PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 25 filers reported holding PROQR THRAPEUTICS N V in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $14,533,000 | -5.7% | 1,814,330 | -1.5% | 0.01% | -10.0% |
Q3 2021 | $15,414,000 | -12.1% | 1,841,578 | -29.2% | 0.01% | -16.7% |
Q2 2021 | $17,527,000 | +2.0% | 2,600,427 | 0.0% | 0.01% | -7.7% |
Q1 2021 | $17,189,000 | +56.4% | 2,600,427 | -0.6% | 0.01% | +62.5% |
Q4 2020 | $10,989,000 | -12.9% | 2,616,473 | -0.7% | 0.01% | -20.0% |
Q3 2020 | $12,618,000 | -21.0% | 2,634,140 | +0.3% | 0.01% | -28.6% |
Q2 2020 | $15,963,000 | +11.3% | 2,625,514 | +0.5% | 0.01% | -17.6% |
Q1 2020 | $14,342,000 | -45.0% | 2,612,306 | -0.7% | 0.02% | -34.6% |
Q4 2019 | $26,070,000 | +72.8% | 2,630,626 | +0.4% | 0.03% | +62.5% |
Q3 2019 | $15,086,000 | -41.8% | 2,619,012 | -8.1% | 0.02% | -38.5% |
Q2 2019 | $25,925,000 | -35.3% | 2,848,928 | -1.4% | 0.03% | -35.0% |
Q1 2019 | $40,065,000 | -15.2% | 2,888,593 | -3.6% | 0.04% | -24.5% |
Q4 2018 | $47,266,000 | -18.5% | 2,995,305 | -0.1% | 0.05% | 0.0% |
Q3 2018 | $58,013,000 | +166.6% | 2,998,094 | +0.6% | 0.05% | +152.4% |
Q2 2018 | $21,763,000 | +139.9% | 2,981,205 | +1.0% | 0.02% | +133.3% |
Q1 2018 | $9,072,000 | +6.7% | 2,950,374 | +11.9% | 0.01% | +12.5% |
Q4 2017 | $8,500,000 | -28.7% | 2,635,552 | +7.3% | 0.01% | -33.3% |
Q3 2017 | $11,918,000 | -7.3% | 2,457,360 | -0.6% | 0.01% | -14.3% |
Q2 2017 | $12,858,000 | -0.5% | 2,472,608 | -4.3% | 0.01% | 0.0% |
Q1 2017 | $12,925,000 | +2.0% | 2,585,047 | 0.0% | 0.01% | 0.0% |
Q4 2016 | $12,667,000 | -27.4% | 2,585,047 | -1.2% | 0.01% | -26.3% |
Q3 2016 | $17,455,000 | +35.0% | 2,616,967 | -2.1% | 0.02% | +35.7% |
Q2 2016 | $12,934,000 | -0.9% | 2,672,377 | -0.1% | 0.01% | 0.0% |
Q1 2016 | $13,053,000 | +50.1% | 2,674,844 | +167.0% | 0.01% | +55.6% |
Q4 2015 | $8,695,000 | -38.4% | 1,001,774 | +3.4% | 0.01% | -35.7% |
Q3 2015 | $14,115,000 | -12.4% | 968,755 | +0.2% | 0.01% | -6.7% |
Q2 2015 | $16,110,000 | -23.6% | 966,433 | +0.3% | 0.02% | -21.1% |
Q1 2015 | $21,081,000 | +70.7% | 963,465 | +69.0% | 0.02% | +58.3% |
Q4 2014 | $12,351,000 | +14.0% | 569,958 | -9.6% | 0.01% | +20.0% |
Q3 2014 | $10,836,000 | – | 630,370 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 1,922,570 | $19,053,000 | 7.16% |
DAFNA Capital Management LLC | 1,114,000 | $11,040,000 | 3.79% |
RTW INVESTMENTS, LP | 4,779,135 | $47,361,000 | 1.79% |
Kerrisdale Advisers, LLC | 448,880 | $4,448,000 | 1.57% |
SPHERA FUNDS MANAGEMENT LTD. | 805,000 | $7,978,000 | 0.66% |
Artal Group S.A. | 1,300,000 | $12,883,000 | 0.50% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,571,319 | $45,302,000 | 0.11% |
ALTRINSIC GLOBAL ADVISORS LLC | 221,360 | $2,194,000 | 0.09% |
COWEN AND COMPANY, LLC | 103,727 | $1,028,000 | 0.09% |
FRANKLIN STREET ADVISORS INC /NC | 60,000 | $595,000 | 0.07% |